Oragenics (NYSEAMERICAN:OGEN – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.51) earnings per share for the quarter, FiscalAI reports.
Oragenics Price Performance
Shares of NYSEAMERICAN OGEN opened at $0.60 on Friday. The stock has a market capitalization of $2.59 million, a P/E ratio of -0.03 and a beta of 1.26. Oragenics has a 1-year low of $0.50 and a 1-year high of $9.60. The business has a fifty day moving average price of $0.70 and a 200 day moving average price of $0.85.
Institutional Investors Weigh In On Oragenics
A number of hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new stake in Oragenics in the fourth quarter valued at about $26,000. Bank of America Corp DE raised its stake in Oragenics by 7,374.0% in the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after buying an additional 15,338 shares during the last quarter. Sabby Management LLC purchased a new stake in Oragenics in the third quarter valued at about $77,000. Finally, DRW Securities LLC raised its stake in Oragenics by 82.4% in the fourth quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock valued at $88,000 after buying an additional 50,900 shares during the last quarter. 18.71% of the stock is currently owned by hedge funds and other institutional investors.
Oragenics Company Profile
Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.
The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.
Recommended Stories
- Five stocks we like better than Oragenics
- 3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill
- 3 Under-The-Radar Small Caps Making New All-Time Highs
- 3 Ways to Target the Resources Powering AI and Data Centers
- Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
